Jung Sun Kim

Jung Sun Kim

Auto-generated profile, based on publicly available information

Jung Sun Kim

Department of Pharmacy, Kangwon National University, Chuncheon, Korea

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Open access
PDF file
AJAlexander Jahn
Alexander Jahn
SKSeok Yong Kim
Seok Yong Kim
JCJoon-Ho Choi
Joon-Ho Choi
DKDae-Duk Kim
Dae-Duk Kim
YAYoung-Joon Ahn
Young-Joon Ahn
JKJung Sun Kim
Jung Sun Kim
Objectives: Vector-borne diseases are still a major mortality factor in Africa and South-east Asia and effective mosquito repellents are therefore needed. An efficient and safe in-vitro assay system using artificial blood and skin substitute could facilitate the development of novel repellents, as most assays currently rely on human subjects or vertebrate whole blood. Moreover, examining the skin permeation profiles could provide safer mosquito repellents. The new assay system could serve as an initial system for testing new repellent candidates upon validation with DEET and its analogues. Methods: N,N-Diethyl-meta-toluamide (DEET) and five analogues were synthesised and used to validate a novel in-vitro bioassay using artificial blood and collagen membrane. Repellency against Aedes aegypti was correlated with lipophilicity and skin permeation. Key findings: The new in-vitro assay showed good reproducibility (interday relative standard deviation <10% at high concentrations). Four of the five DEET analogues showed repellency similar or superior to that of DEET. Repellency correlated linearly with lipophilicity but stronger repellents tended to permeate skin better. Conclusions: The new in-vitro assay using blood substitute and collagen membrane significantly simplifies screening of possible mosquito repellents. Lipophilicity as well as skin permeation profiles should be considered before testing of compounds that are candidates for mosquito repellents.

13 June 2025 in Pharmacogenomics
Verified
Journal Article
Closed access
JKJungsun Kim
Jungsun Kim
JHJi Min Han
Ji Min Han
JYJeong Yee
Jeong Yee
YKYoung Ju Kim
Young Ju Kim
SCSuk Joo Choi
Suk Joo Choi
Hye Sun GwakHye Sun Gwak
Hye Sun Gwak
Nifedipine, a substrate of ATP-binding cassette superfamily G member 2 (ABCG2), is a tocolytic agent. This study aimed to construct a scoring system by exploring the association between ABCG2 polymorphisms and the treatment response of nifedipine in pregnant women. This study was conducted at a tertiary medical center. Eight single-nucleotide polymorphisms from the ABCG2 gene were selected. The adjusted OR (AOR) were calculated using multivariable analysis. A risk scoring system was constructed by dividing the AOR of independent risk factors by the minimum AOR to predict treatment failure. A total of 69 patients were analyzed for treatment failure. Maternal age ≥33 years, contraction interval <4 minutes, and contraction intensity ≥20 mmHg were clinical risk factors associated with treatment failure. Patients with the ABCG2 rs2622604 and rs4148157 experienced an 8.6-fold and 4.3-fold increased risk of treatment failure, respectively. The predicted risks of treatment failure of patients who scored 0, 1-2, 3-4, 5-6, 7-8, and 9 points were 2.8%, 9.1%, 26.0%, 55.4%, 81.4%, and 93.9%, respectively. This novel risk scoring system may aid clinicians in identifying patients less likely to respond to nifedipine, improving individualized care in preterm labor management.

Verified
Journal Article
Open access
PDF file
EJEun Jeong Jang
Eun Jeong Jang
DLDa Hoon Lee
Da Hoon Lee
YSYubin Song
Yubin Song
JKJung Sun Kim
Jung Sun Kim
YKYoung Ju Kim
Young Ju Kim
Hye Sun GwakHye Sun Gwak
Hye Sun Gwak
Objectives: Ritodrine, a tocolytic agent used to delay preterm labor, can cause several cardiovascular-associated adverse events (AEs). This study aimed to examine the relationship between gene polymorphisms in peroxisome proliferator-activated receptor gamma (PPARG) and PPARG coactivator-1α (PPARGC1A) and the occurrence of ritodrine-induced AEs. Additionally, a risk-scoring system was developed to identify patients at high risk of AEs. Methods: Patients aged 18 years or older who were administered ritodrine to manage preterm labor with intact membranes and uterine contractions occurring at 20–36 weeks of gestation were enrolled in this study. A total of 70 common PPARG and PPARGC1A variants (minor allele frequency ≥ 0.2) with low linkage disequilibrium (r2 < 0.8) were selected from an Axiom™ Precision Medicine Research Array (AMPRA). Results: A total of 149 patients were included in the analysis. After adjusting for confounders (age, gestational age, and the maximum infusion rate), weight and rs2946385, rs35523565, and rs2240748 of PPARGC1A were identified as significant predictors associated with ritodrine-induced AEs. Based on the risk-scoring system, the predicted probabilities of AEs for patients with scores of 0, 1, 2, 3, 4, and 5 points were 4%, 9%, 18%, 35%, 55%, and 74%, respectively. The AUROC for the risk score predicting ritodrine-induced AEs was 0.729 (95% CI: 0.672–0.831, p < 0.001). Conclusions: This study indicates that ritodrine-induced AEs are related to PPARGC1A polymorphisms. A risk-scoring system based on genetic variants showed moderate predictive ability for ritodrine-induced AEs, suggesting potential utility in females with preterm labor.

31 December 2025 in Korean Journal of Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
DKDasom Kim
Dasom Kim
EJEun Jeong Jang
Eun Jeong Jang
JKJungsun Kim
Jungsun Kim
Dasom Kim, Eun Jeong Jang, and Jungsun Kim. Korean J Clin Pharm 2025;35:226-33. https://doi.org/10.24304/kjcp.2025.35.4.226

10 October 2025 in International Journal for Parasitology: Drugs and Drug Resistance
Verified
Journal Article
Open access
DKDasom Kim
Dasom Kim
DLDa Hoon Lee
Da Hoon Lee
YSYubin Song
Yubin Song
JKJung Sun Kim
Jung Sun Kim
Hye Sun GwakHye Sun Gwak
Hye Sun Gwak
Severe malaria remains a major cause of morbidity and mortality worldwide. Early identification of patients at high risk of poor response to treatment is essential, yet no simple clinical tool is currently available. This study aimed to develop a risk scoring system to predict failure to artesunate therapy. This retrospective study included adult patients (aged ≥18 years) who received at least one dose of intravenous artesunate at the National Medical Center in South Korea between 2014 and 2023. Treatment failure (early or late clinical failure) was the response variable, which was defined according to WHO criteria. Candidate predictor variables included demographic, clinical, parasitological, and laboratory parameters. Odds ratios (ORs) and adjusted odds ratios (aORs) were calculated using univariate and multivariable logistic regression analyses, respectively. Final predictors were selected through backward elimination based on the Likelihood Ratio criterion, and a clinical risk scoring system was developed based on the adjusted ORs. Among 98 patients included in the final analysis, treatment failure occurred in 12 (12.2 %). Multivariable analysis identified female sex, parasitemia >5 %, and impaired consciousness as independent risk factors. Using these variables, a risk-scoring system was constructed, and the predicted probabilities of treatment failure for patients with scores of 0, 1, 2, 3, and 4 points were 5 %, 16 %, 41 %, 72 %, and 90 %, respectively (AUROC = 0.768, 95 % CI: 0.605-0.931). Parasitemia >5 %, impaired consciousness, and female sex were predictive of artesunate treatment failure as defined by WHO clinical criteria. The developed risk scoring system provides a practical tool for identifying high-risk patients requiring intensified monitoring and alternative treatment strategies. These findings are derived from a South Korean cohort and should be interpreted with caution when extrapolated to endemic populations.

1 January 2026 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
DLDa Hoon Lee
Da Hoon Lee
YPYoon-A Park
Yoon-A Park
SCSeo-A Choi
Seo-A Choi
YSYubin Song
Yubin Song
JKJung Sun Kim
Jung Sun Kim
Hye Sun GwakHye Sun Gwak
Hye Sun Gwak
Lee DH, et al. Yonsei Med J. 2026 ;67:e19. https://doi.org/10.3349/ymj.2025.0181